888-776-0942 from 8 AM - 10 PM ET
Full Commercial Launch Underway for One of the Most Studied and Thinnest Strut Drug-Eluting Stents, Offering Enhanced Deliverability
LAKE OSWEGO, Ore. , Sept. 29, 2021 /PRNewswire/ -- BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer drug-eluting stent system (BP-DES). The company also announced the first U.S. implant and full commercial launch of the new DES system, which offers advanced deliverability and an ultrathin strut design considered the thinnest available in the United States .
"We welcome the availability of the Orsiro Mission DES in the US as a novel percutaneous coronary intervention device offering better outcomes," said Dr. David Kandzari , Chief of the Piedmont Heart Institute and Cardiovascular Service Line; Director, Interventional Cardiology of the Piedmont Heart Institute; and Chief Scientific Officer for Piedmont Healthcare in Atlanta , USA , whose facility is among the first to receive the newly approved device. "The outstanding deliverability and the extensive clinical data give strong evidence for continued Orsiro Mission adoption."
The Orsiro DES is one of the most studied stents available today throughout numerous randomized controlled trials (RCTs), registries and meta-analyses1. The Orsiro Mission DES features the same proprietary stent design and innovative bioabsorbable coating with controlled drug release as the Orsiro stent. Improvements to the new Orsiro Mission DES system include a re-engineered delivery system and a new deep embedding process to further improve deliverability, including 'best in class' trackability and crossability2.
The key highlights from the Orsiro drug-eluting stent clinical program demonstrating outstanding outcomes3:
"We will continue to bolster our interventional cardiology portfolio with innovations like the Orsiro Mission and state-of-the-art PK Papyrus® covered stent system to support and improve patient care," said David Hayes , M.D., Chief Medical Officer, BIOTRONIK, Inc. "This emphasizes our commitment to excellence and reinforces our vision to ensure the highest quality."
Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.
All other trademarks or registered trademarks cited herein are the property of their respective owners.
About Orsiro® Mission: https://us.orsiro.com/orsiromission
About BIOTRONIK: BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany , and is represented in over 100 countries.
More news releases in similar topics
Cision Distribution 888-776-0942 from 8 AM - 9 PM ET